Clinical trials: Motor Vehicle Accident
Hepatitis B
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
This is an open-label study to determine the safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV vaccines, with or without nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral…
- Trial name
- NCT04778904
- Testing
- ChAdOx1-HBV, MVA-HBV, Nivolumab
- Where
- 12 sites in South Korea, Taiwan and 1 more
- Volunteers
- 55 people
- Sponsor
- Barinthus Biotherapeutics
Teen Drivers, Motor Vehicle Accidents
Promoting Intrafamily Accountability for Reducing Cellphone Use While Driving in Adults and Their Teen Children
Research participants and their parents will be recruited to take part in a randomized control trial. Participants' and their parents' cellphone use will be observed during an initial baseline period.
- Trial name
- NCT02923271
- Testing
- CellControl
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo.
- Trial name
- NCT02564523
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
This Phase 2 study aims to improve preparedness for future Ebola outbreaks by vaccination of a well-known population at risk, ie, a cohort of health care providers (HCP) (such as primary, emergency, and community health care…
- Trial name
- EBOVAC3DRC (NCT04186000)
- Testing
- Ad26.ZEBOV vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Ebola
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3…
- Trial name
- NCT04228783
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Lung Cancer, Breast Cancer
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
Background: This cancer vaccine was developed to help teach the body's immune system to attack and destroy cancer cells. It teaches immune cells to target the Brachyury protein.
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer, Tumors (Others)
- Trial name
- NCT02179515
- Testing
- MVA-brachyury- TRICOM
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Smallpox
ACAM 3000 MVA at Harvard Medical School
The purpose of this study is to assess the safety of an experimental smallpox vaccine (MVA: Modified Vaccinia Ankara) and to compare the body's immune (system that fights disease) response to this vaccine.
- Trial name
- NCT00133575
- Testing
- MVA Smallpox Vaccine, Live vaccinia virus vaccine
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Viral Disease
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.
- Trial name
- NCT02416453
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 11 sites in France, United Kingdom
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hemorrhagic Fever, Ebola
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
- Trial name
- NCT02661464
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 16 sites in United States, Burkina Faso and 5 more
- Volunteers
- 677 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Pregnancy, Sexually Transmitted Infections
Teen Video Study to Reduce Risky Driving and Sexual Behavior in Adolescents
The purpose of this study is to measure the effects of an interactive video on adolescent risky behaviors and outcomes, with one video intended to reduce teen pregnancies and the other intended to reduce automobile accidents.
- Conditions
- Pregnancy, Sexually Transmitted Infections, Automobile Accidents
- Trial name
- TVS (NCT02049710)
- Testing
- Seventeen Days, Driving Skills for Life
- Where
- 3 sites in United States
- Volunteers
- 1,317 people
- Sponsor
- Carnegie Mellon University
Teen Drivers, Motor Vehicle Accident
Way to Safety Cellphone Blocking
Research participants will be recruited to take part in a randomized control trial. Participants' cellphone use will be observed during an initial baseline period.
- Trial name
- NCT02416713
- Testing
- Cellcontrol DriveID, Education Only
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Smallpox
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.
- Trial name
- NCT01144637
- Testing
- IMVAMUNE®
- Where
- 34 sites in United States
- Volunteers
- 4,005 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Hepatitis C
Staged Phase I/II Hepatitis C Prophylactic Vaccine
A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45.
- Trial name
- NCT01436357
- Testing
- AdCh3NSmut1, MVA-NSmut
- Where
- 5 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Microvascular Coronary Artery Disease
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically…
- Trial name
- NCT03236311
- Testing
- SAR407899, Adenosine, Regadenoson
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 10 people
- Sponsor
- Sanofi
HIV Infections
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or…
- Trial name
- NCT02852005
- Testing
- MVA/HIV62B vaccine, AIDSVAX B/E vaccine
- Where
- 9 sites in United States, Peru
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was…
- Trial name
- NCT02919306
- Testing
- Ad26.Mos.HIV, MVA-Mosaic
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS).
- Trial name
- NCT02873286
- Testing
- MVA-BN-RSV
- Where
- 12 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Human Immunodeficiency Virus
Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women
A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA combinations in order to maximise antibody responses to Human Immunodeficiency Virus
- Trial name
- Ad4HIV (NCT03408262)
- Testing
- Ad4-EnvCN54, MVA-CN54, CN54gp140/MPLA
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.